8-K: GlycoMimetics Phase 3 Trial Fails to Meet Primary Endpoint, Company to Present Data at Medical Meeting

GlycoMimetics' Phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia did not meet its primary endpoint of overall survival, though the company plans to present a comprehensive data analysis at an upcoming medical meeting.

Summary

• GlycoMimetics announced topline results from its Phase 3 clinical trial of uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML).
• The study, which included 388 patients, did not show a statistically significant improvement in overall survival for patients treated with uproleselan combined with chemotherapy compared to chemotherapy alone.
• Patients receiving uproleselan had a median overall survival of 13 months, while those on the placebo arm had a median overall survival of 12.3 months.
• The company is conducting a comprehensive data analysis with medical, statistical, and regulatory experts.
• GlycoMimetics intends to submit the results for presentation at an upcoming medical meeting.
• The company also reported preliminary financial results for the first quarter of 2024, with cash and cash equivalents of $31.3 million as of March 31, 2024.
• Research and development expenses increased to $6.0 million for the quarter, while general and administrative expenses decreased to $5.1 million.
• The company has 64,450,835 shares of common stock outstanding as of March 31, 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the failure of the Phase 3 trial to meet its primary endpoint, despite the company's efforts to highlight ongoing studies and other pipeline programs. The lack of a significant improvement in overall survival is a major setback.

Positives

• The company is thoroughly analyzing the data in collaboration with medical, statistical and regulatory experts.
• GlycoMimetics is committed to submitting a comprehensive data analysis for presentation at an upcoming medical meeting.
• The NCI Phase 2/3 study in newly diagnosed AML patients remains ongoing.
• The company's general and administrative expenses decreased for the quarter ended March 31, 2024.
• The company has a novel small molecule drug discovery platform.

Negatives

• The Phase 3 trial of uproleselan in relapsed/refractory AML did not meet its primary endpoint of overall survival.
• The median overall survival for patients treated with uproleselan was only 0.7 months longer than the placebo group.
• The company's cash position decreased from $41.8 million at the end of 2023 to $31.3 million as of March 31, 2024.
• Research and development expenses increased for the quarter ended March 31, 2024.

Risks

• The failure of the Phase 3 trial to meet its primary endpoint may impact the future development and regulatory approval of uproleselan.
• The company's cash position has decreased, which may require additional funding in the future.
• There are risks associated with the development of new drugs, including unexpected safety or efficacy data and changes in the regulatory environment.
• The company is dependent on the success of its clinical trials and regulatory approvals.

Future Outlook

The company plans to submit a comprehensive data analysis for presentation at an upcoming medical meeting and is updating uproleselan plans and evaluating financial guidance. The NCI Phase 2/3 study in newly diagnosed AML patients remains ongoing.

Management Comments

• Harout Semerjian, Chief Executive Officer of GlycoMimetics, stated that while the outcome of the Phase 3 study in R/R AML is not what they hoped, they wish to thank the investigators, the participating patients and their families for their dedication to this large, well-controlled randomized study.
• Management is thoroughly analyzing the data in collaboration with medical, statistical and regulatory experts.

Industry Context

The failure of the Phase 3 trial highlights the challenges in developing new treatments for AML, a disease with a poor prognosis and a high unmet medical need. The company is still pursuing other avenues for uproleselan and other drug candidates.

Comparison to Industry Standards

• The median overall survival of 13 months in the uproleselan arm is not significantly better than the 12.3 months in the placebo arm, and is not a significant improvement over historical benchmarks for intensive chemotherapy in R/R AML which are around 6 months.
• Other trials in R/R AML have shown varying results, with some achieving improvements in overall survival, such as the VYXEOS trial with a median OS of 9.5 months vs 5.9 months for the control arm, and the ADMIRAL trial with a median OS of 9.3 months vs 5.6 months for the control arm.
• The results of the uproleselan trial are not as positive as some other recent trials in AML, such as the VIALE-A trial which showed a median OS of 15 months vs 10 months for the control arm.
• The company's ongoing NCI-sponsored Phase 2/3 study in newly diagnosed AML is a different patient population and may yield different results.

Stakeholder Impact

• Shareholders may be negatively impacted by the failure of the Phase 3 trial.
• Patients with relapsed/refractory AML may not benefit from uproleselan as a treatment option based on these results.
• Employees may be affected by any changes in the company's strategy or financial situation.
• The company's partners and collaborators may need to reassess their involvement with uproleselan.

Next Steps

• The company will conduct a comprehensive data analysis of the Phase 3 trial results.
• GlycoMimetics plans to submit the results for presentation at an upcoming medical meeting.
• The company will continue the NCI Phase 2/3 study in newly diagnosed AML patients.
• GlycoMimetics is updating uproleselan plans and evaluating financial guidance.

Key Dates

Keywords

uproleselan, AML, acute myeloid leukemia, clinical trial, Phase 3, glycomimetics, oncology, cancer, E-selectin, chemotherapy, overall survival, R/R AML, GMI-1687, Galectins